Adversity is less terrifying than hope: Tango Therapeutics Inc (TNGX)

With 0.55 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.02 million shares. The 52-week range on TNGX shows that it touched its highest point at $12.02 and its lowest point at $2.35 during that stretch. It currently has a 1-year price target of $11.50. Beta for the stock currently stands at 0.80.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TNGX was down-trending over the past week, with a drop of -5.98%, but this was down by -23.38% over a month. Three-month performance dropped to -34.44% while six-month performance fell -78.76%. The stock lost -79.88% in the past year, while it has lost -23.62% so far this year. A look at the trailing 12-month EPS for TNGX yields -1.17 with Next year EPS estimates of -1.42. For the next quarter, that number is -0.34. This implies an EPS growth rate of -11.20% for this year and -18.07% for next year.

Float and Shares Shorts:

At present, 107.41 million TNGX shares are outstanding with a float of 48.35 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TNGX since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.12026 being high and -$1.27165 being low. For TNGX, this leads to a yearly average estimate of -$1.201. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.46. The average estimate for the next quarter is thus -$0.37.